PepDiana
Back to Evidence
Paper-scoped peptide mentionSequence reported

LCKLSL

PMC12207141::PEP000001

Source publication

Targeting Annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer.

Journal for Immunotherapy of Cancer · 2025

DOI 10.1136/jitc-2025-011716PMC12207141PMID 40571481
Sequence status
reported
Standardization
Sequence ready
Source location
unknown
Activity records
3

Sequence evidence

Reported molecular identity

LCKLSL

LCKLSL

Resolved peptide links

PEPDIA-PLP-001707

Experimental observations

Records linked to this mention

ImmunomodulatoryAntibacterialPositive observation
Record detail

Figure 5D: The decreased Annexin A2-immunoprecipitated HSP90 and the decreased HSP90-immunoprecipitated Annexin A2 under the treatments of ... 10 µM hexapeptide LCKLSL (HEXA).

Mention PMC12207141::PEP000001PMC12207141figure
Measure
percent_inhibition
Value
decreased
Target
Huh-7
Assay
Not reported by source
Source publication
ImmunomodulatoryAntibacterialPositive observation
Record detail

Figure 5I: All of them [matrine, PY60, and hexapeptide] increased the HSP90-immunoprecipitated TAP1 contents.

Mention PMC12207141::PEP000001PMC12207141figure
Measure
percent_inhibition
Value
increased
Target
Huh-7
Assay
Not reported by source
Source publication
AnticancerCytotoxicPositive observation
Record detail

Figure 5K: The LDH release experiment showed that the treatments of matrine, PY60, and hexapeptide enhanced the killing of human CD8+ T cells on human Huh7 cells.

Mention PMC12207141::PEP000001PMC12207141figure
Measure
percent_inhibition
Value
enhanced
Target
Homo sapiens
Assay
Not reported by source
Source publication

Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.